Mariangela Agamennone

Dr. Mariangela Agamennone

University "G. d'Annunzio" of Chieti-Pescara, Department of Pharmacy
orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2012 in Pathogens and Global Health
Verified
Journal Article
Closed access
MAMaria Grazia Ammendolia
Maria Grazia Ammendolia
Mariangela AgamennoneMariangela Agamennone
Mariangela Agamennone
APAgostina Pietrantoni
Agostina Pietrantoni
FLFabio Lannutti
Fabio Lannutti
Rosa Anna SicilianoRosa Anna Siciliano
Rosa Anna Siciliano
FSFabiana Superti
Fabiana Superti
Bovine lactoferrin (bLf) is a multifunctional glycoprotein that plays an important role in innate immunity against infections, including influenza. Here we have dissected bLf into its C- and N-lobes and show that inhibition of influenza virus hemagglutination and cell infection is entirely attributable to the C-lobe and that all major virus subtypes, including H1N1 and H3N2, are inhibited. By far-western blotting and sequencing studies, we demonstrate that bLf C-lobe strongly binds to the HA(2) region of viral hemagglutinin, precisely the highly conserved region containing the fusion peptide. By molecular docking studies, three C-lobe fragments were identified which inhibited virus hemagglutination and infection at fentomolar concentration range. Besides contributing to explain the broad anti-influenza activity of bLf, our findings lay the foundations for exploiting bLf fragments as source of potential anti-influenza therapeutics.

17 January 2006 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
GPGiorgio Pochetti
Giorgio Pochetti
EGEnrico Gavuzzo
Enrico Gavuzzo
CCCristina Campestre
Cristina Campestre
Mariangela AgamennoneMariangela Agamennone
Mariangela Agamennone
PTPaolo Tortorella
Paolo Tortorella
FMFernando Mazza
Fernando Mazza

1 January 2006 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
CCCristina Campestre
Cristina Campestre
Mariangela AgamennoneMariangela Agamennone
Mariangela Agamennone
PTPaolo Tortorella
Paolo Tortorella
SPSerena Preziuso
Serena Preziuso
ABAlessandro Biasone
Alessandro Biasone
CGCarlo Gallina
Carlo Gallina

11 January 2019 in Viruses
Verified
Journal Article
Open access
PDF file
FSFabiana Superti
Fabiana Superti
Mariangela AgamennoneMariangela Agamennone
Mariangela Agamennone
APAgostina Pietrantoni
Agostina Pietrantoni
MAMaria Grazia Ammendolia
Maria Grazia Ammendolia
Bovine lactoferrin (bLf) is an iron-binding glycoprotein folded in two symmetric globular lobes (N- and C-lobes) with potent antimicrobial and immunomodulatory activities. Recently, we have shown that bLf, and in particular its C-lobe, interacts with influenza A virus hemagglutinin and prevents infection by different H1 and H3 viral subtypes. Influenza virus hemagglutinin (HA), and in particular its highly conserved fusion peptide involved in the low-pH-mediated fusion process, plays a significant role in the early steps of viral infection and represents an attractive target for the development of anti-influenza drugs. In the present research, we further investigated the influence of low pH on the interactions between bLf and influenza A H1N1 virus by different techniques, such as enzyme-linked immunosorbent assay, electron microscopy, hemolysis inhibition assay, and time course assay. Our results demonstrate that lactoferrin interaction with influenza hemagglutinin at low pH induces alterations that stabilize the conformation of the hemagglutinin, resulting in the inhibition of the fusion peptide activity. Taken together, our data allowed to better characterize the HA-specific inhibiting activity of bLf and to confirm HA as a good target for drug development.

15 March 2011 in ChemMedChem
Verified
Journal Article
Closed access
PDF file
MRMaria Teresa Rubino
Maria Teresa Rubino
Mariangela AgamennoneMariangela Agamennone
Mariangela Agamennone
CCCristina Campestre
Cristina Campestre
Pietro CampigliaPietro Campiglia
Pietro Campiglia
VCViviana Cremasco
Viviana Cremasco
PTPaolo Tortorella
Paolo Tortorella

9 March 2021 in Molecules
Verified
Journal Article
Open access
PDF file
Alessandra AmmazzalorsoAlessandra Ammazzalorso
Alessandra Ammazzalorso
Mariangela AgamennoneMariangela Agamennone
Mariangela Agamennone
Barbara De FilippisBarbara De Filippis
Barbara De Filippis
MARIALUIGIA FANTACUZZIMARIALUIGIA FANTACUZZI
MARIALUIGIA FANTACUZZI
The inhibition of cyclin dependent kinases 4 and 6 plays a role in aromatase inhibitor resistant metastatic breast cancer. Three dual CDK4/6 inhibitors have been approved for the breast cancer treatment that, in combination with the endocrine therapy, dramatically improved the survival outcomes both in first and later line settings. The developments of the last five years in the search for new selective CDK4/6 inhibitors with increased selectivity, treatment efficacy, and reduced adverse effects are reviewed, considering the small-molecule inhibitors and proteolysis-targeting chimeras (PROTACs) approaches, mainly pointing at structure-activity relationships, selectivity against different kinases and antiproliferative activity.